Ad Header

PharmaLive

Slogan

The Pulse of the Pharmaceutical Industry

  • Filter By Category

  • Filter By Author

Morphosys to boost size of tafasitamab drug trial on encouraging interim data

Morphosys said more patients would be recruited for a study testing the German biotech company’s most advanced drug against a common type of blood cancer, following an encouraging interim data readout.

Read More »

Bristol-Myers posts better-than-expected results, Opdivo growth slows

U.S. drugmaker Bristol-Myers Squibb Co. reported higher-than-expected third-quarter 2019 profit, helped by strong sales of the blood thinner Eliquis, even as growth of the company’s blockbuster cancer treatment Opdivo slowed.

Read More »

FDA Approves Janssen’s Darzalex Combo Regimen for Newly Diagnosed, Transplant-Eligible Patients with MM

The U.S. Food and Drug Administration approved Janssen’s Darzalex (daratumumab) in combination with bortezomib, thalidomide and dexamethasone for newly diagnosed patients with multiple myeloma who are eligible for autologous stem cell transplant.

Read More »

GSK builds oncology pipeline as drug shown to help myeloma patients

GlaxoSmithKline said an experimental multiple myeloma treatment showed a meaningful response in patients that have run out of three previous treatment options.

Read More »

Calquence Earns Breakthrough Therapy Designation

AstraZeneca’s BTK inhibitor Calquence won Breakthrough Therapy Designation from the U.S. FDA as a monotherapy treatment for patients with chronic lymphocytic leukemia (CLL).

Read More »

FDA Approves Pfizer’s Biosimilar Ruxience for Certain Cancers and Autoimmune Conditions

The U.S. Food and Drug Administration approved Pfizer Inc.’s Ruxience (rituximab-pvvr) – a biosimilar to Rituxan (rituximab) – for the treatment of adult patients with non-Hodgkin’s lymphoma, chronic lymphocytic leukemia, and granulomatosis with polyangiitis and microscopic polyangiitis.

Read More »

Genmab Raises $506 Million in IPO

Copenhagen, Denmark-based Genmab A/S raised $506 million with an initial public offering (IPO), with the company trading on the Nasdaq under the ticker symbol GMAB.

Read More »

ImmunoGen Culls 220 Employees

ImmunoGen shares fell after the company announced the slashing of 220 employees as part of an effort to reduce ongoing expenses while recovering from an FDA rejection of an ovarian cancer drug.

Read More »

FDA declines to approve Daiichi Sankyo’s blood cancer treatment

The U.S. FDA declined to approve Daiichi Sankyo Co.’s drug quizartinib as a treatment for adults with a type of blood cancer.

Read More »

Calquence Significantly Prolonged Time Patients Lived without Disease Progression in Relapsed or Refractory Chronic Lymphocytic Leukemia

AstraZeneca announced detailed results from the interim analysis of the Phase III ASCEND trial at the European Hematology Association Annual Congress in Amsterdam, showing Calquence (acalabrutinib) significantly prolonged the time patients lived without disease progression in relapsed or refractory chronic lymphocytic leukemia.

Read More »

Ad Right Top

MedAdNews

Extensive pharmaceutical business and marketing intelligence. For back issues, please contact MDAD@kmpsgroup.com.

October 2019 Focus: Top 50 Company Profiles & Financials, Outcomes Creativity Index, and more!

Subscribe

Ad Right Bottom